Ensign Peak Advisors, Inc Replimune Group, Inc. Transaction History

Ensign Peak Advisors, Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $3.69 Million - $6.02 Million	215,840 Added 398.47%	270,007 $7.34 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $313,716 - $425,326	20,110 Added 59.05%	54,167 $935,000
Q2 2022 Aug 12, 2022	SELL	$13.32 - $19.98 $1.66 Million - $2.49 Million	-124,469 Reduced 78.52%	34,057 $595,000
Q1 2022 May 16, 2022	SELL	$15.24 - $29.75 $13.9 Million - $27.1 Million	-912,041 Reduced 85.19%	158,526 $2.69 Million
Q4 2021 Feb 11, 2022	SELL	$25.43 - $34.25 $5.58 Million - $7.51 Million	-219,294 Reduced 17.0%	1,070,567 $29 Million
Q3 2021 Nov 12, 2021	SELL	$28.98 - $39.54 $5.03 Million - $6.87 Million	-173,659 Reduced 11.87%	1,289,861 $38.2 Million
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $1.76 Million - $2.43 Million	61,803 Added 4.41%	1,463,520 $56.2 Million
Q1 2021 May 12, 2021	BUY	$30.22 - $45.57 $5.78 Million - $8.72 Million	191,319 Added 15.81%	1,401,717 $42.8 Million
Q4 2020 Feb 12, 2021	BUY	$23.5 - $52.65 $9.34 Million - $20.9 Million	397,440 Added 48.89%	1,210,398 $46.2 Million
Q3 2020 Nov 12, 2020	BUY	$18.85 - $27.0 $3.37 Million - $4.82 Million	178,517 Added 28.14%	812,958 $18.7 Million
Q2 2020 Aug 12, 2020	BUY	$9.76 - $25.95 $4.64 Million - $12.3 Million	475,308 Added 298.69%	634,441 $15.8 Million
Q1 2020 May 11, 2020	BUY	$8.9 - $19.08 $551,123 - $1.18 Million	61,924 Added 63.7%	159,133 $1.59 Million
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $1.13 Million - $1.67 Million	97,209 New	97,209 $1.4 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.